One-Year Outcomes of 1 + pro re nata versus 3 + pro re nata Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration

Publisher： Karger

E-ISSN： 1423-0267|237|2|105-110

ISSN： 0030-3755

Source： Ophthalmologica, Vol.237, Iss.2, 2017-02, pp. : 105-110

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparison of pro re nata versus Bimonthly Injection of Intravitreal Aflibercept for Typical Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 238, Iss. 1-2, 2017-04 ,pp. : 17-22

Karger

Access to resources Recommend Favorite

Outcomes when Switching from a pro re nata Regimen to a Treat and Extend Regimen Using Aflibercept in Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 236, Iss. 4, 2016-12 ,pp. : 201-206

Karger

Access to resources Recommend Favorite

A Case of Sustained Intraocular Pressure Elevation after Multiple Intravitreal Injection of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration

By  

Case Reports in Ophthalmology, Vol. 7, Iss. 1, 2016-04 ,pp. : 230-236

Karger

Access to resources Recommend Favorite

Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration: 12-Month Safety and Efficacy Outcomes

By  

Ophthalmic Research, Vol. 55, Iss. 2, 2016-0 ,pp. : 84-90

Karger

Access to resources Recommend Favorite

One-Year Outcomes of a Treat-and-Extend Regimen of Aflibercept for Exudative Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 237, Iss. 3, 2017-03 ,pp. : 139-144

Karger

Access to resources Recommend Favorite